Fig. 2From: HER3 in cancer: from the bench to the bedsideTherapies against HER3 under clinical development. Monoclonals antibodies (mAbs), bispecific antibodies (bAbs), antibody–drug conjugate (ADC) and other therapies such as HER3 vaccineBack to article page